|
MechanismKATP channels activators |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date22 Jan 1973 |
A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis
The aim of the study is to assess the efficacy and safety of NT-KO-003 in the treatment of relapsing remitting multiple sclerosis, comparing two doses versus placebo.
100 Clinical Results associated with Neurotec Pharma SL
0 Patents (Medical) associated with Neurotec Pharma SL
100 Deals associated with Neurotec Pharma SL
100 Translational Medicine associated with Neurotec Pharma SL